The effect of prophylactic migraine treatment on arterial stiffness


DOĞAN A. , Orscelik O. , Kocyigit M. , ELÇİK D. , Baran O. , Cerit N. , ...More

BLOOD PRESSURE, vol.24, no.4, pp.222-229, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.3109/08037051.2015.1030902
  • Title of Journal : BLOOD PRESSURE
  • Page Numbers: pp.222-229
  • Keywords: arterial stiffness, endothelial dysfunction, migraine, prophylaxis, PULSE-WAVE VELOCITY, CARDIOVASCULAR RISK-FACTORS, STAGE RENAL-DISEASE, ENDOTHELIAL DYSFUNCTION, AORTIC STIFFNESS, HYPERTENSIVE PATIENTS, BLOOD-PRESSURE, YOUNG-WOMEN, ALL-CAUSE, HEADACHE

Abstract

Background. Migraine is a common type of primary headache predominantly seen in women. This study aimed to evaluate endothelial function in patients with migraine using pulse wave velocity (PWV). Methods. The study included 73 patients with newly diagnosed migraine and 80 healthy subjects. All patients and controls underwent baseline transthoracic echocar-diography and PWV measurements. Patients were randomized to three groups to receive propranolol, flunarizine or topiramate, and the measurements were repeated at the end of 1 month. Results. The newly diagnosed migraine patients and the control group exhibited no differences in baseline clinical characteristics, and the measurements showed that PWV was 7.4 +/- 1.0 m/s in the patient group and 6.0 +/- 1.0 m/s in the control group (p < 0.001). The same measurements were repeated during a control visit at the end of 1 month. Following treatment, a significant decrease was observed in PWV in all patient groups compared to baseline (p < 0.001). Subgroup analysis showed significantly decreased PWV in all drug groups, with the most prominent decrease in the topiramate group. Conclusions. The increased PWV demonstrated in migraine patients in this study stands out as an additional parameter elucidating endothelial dysfunction in these patients. Decreasing the number of migraine attacks with prophylactic treatment may reduce PWV and decrease cardiovascular risk in long-term follow-up.